Skip to main content
News

Hormone Therapy Recalled


November 18, 2016

Wells Pharmacy Network is voluntary recalling its Estradiol 3-mg pellets. More than 300 pellets that were distributed throughout the United States are affected by this ongoing, Class III recall.

The US Food and Drug Administration (FDA) Enforcement Report for the week of November 16 listed the reason for recall as “Superpotent and Subpotent drugs.”

------

Related Content

Rivaroxaban Superior to Warfarin for NVAF

Managing Heart Failure in Long-Term Care

------

The code information for the impacted hormone pellets is as follows: lot number 08082016@1, BUD: 02/04/2017.

Wells Pharmacy Network started notifying consumers about the recall via telephone on September 19.

The FDA gave this a Class III designation on November 8.

Wells Pharmacy Network is a nationwide compounding pharmacy.--Meredith Edwards White

Reference

http://www.accessdata.fda.gov/scripts/ires/index.cfm

Back to Top